| abstract |
This invention provides methods of identifying and treating cancer patients having activating alterations in the PEST domain of Notch1, Notch2 or Notch3, who will benefit from treatment with a Notch signaling pathway inhibitor, such as the γ-secretase inhibitor PF-03084014, or a pharmaceutically acceptable salt thereof. |